Lenz discusses the link between HER2 expression and responses with mCRC treatment regimens and how HER2 expression can guide treatment decision-making.
Back
Retrospective Data Show Link Between HER2 Expression and Survival Outcomes in mCRC
Heinz-Josef Lenz, MD, discusses the findings of a retrospective study examining the correlation between HER2 expression and treatment outcomes in colorectal cancer.
Retrospective Data Show Link Between HER2 Expression and Survival Outcomes in mCRC
Episodes
All
All
HER2 gene expression is associated with prognostic and predictive value in patients with metastatic colorectal cancer.
Heinz-Josef Lenz, MD, FACP, discusses the prognostic and predictive value of HER2 expression levels in select patients with colorectal cancer.
Heinz-Josef Lenz, MD, FACP, discusses the prognostic value of HER2 expression in patients with KRAS wild-type metastatic colorectal cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
3
Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments
4
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
5